Matches in SemOpenAlex for { <https://semopenalex.org/work/W3147697734> ?p ?o ?g. }
- W3147697734 endingPage "480" @default.
- W3147697734 startingPage "473" @default.
- W3147697734 abstract "Précis: No significant difference was found between the intraocular pressure (IOP) lowering of omidenepag isopropyl 0.002% once daily (QD) and twice daily (BID). However, adverse events (AEs) were higher in the BID arm; thus, QD dosing is the preferred dosing frequency for further investigation. Purpose: This phase 2, randomized, double-masked, parallel-arm, multicenter study (NCT03858894) was conducted in the United States to examine whether the efficacy and safety of omidenepag isopropyl 0.002% BID dosing was superior to QD dosing in subjects with primary open-angle glaucoma or ocular hypertension. Methods: Randomized subjects (1:1) received omidenepag isopropyl 0.002% QD (n=50) or BID (n=48) for 6 weeks (after a ≤4-week washout period). IOP was measured at 8:00 am , 12:00 pm , and 4:00 pm at baseline and weeks 2 and 6. The primary efficacy endpoint was IOP at each timepoint at weeks 2 and 6. AEs were evaluated. Results: Baseline mean diurnal IOP (±SD) post washout was 25.4±2.9 mm Hg (BID) and 24.6±1.9 mm Hg (QD). At weeks 2 and 6, clinically significant IOP reductions from baseline were observed for omidenepag isopropyl BID and QD treatments. Least-squares mean (±SE) IOP differences (BID versus QD) were not statistically significant (week 2: 0.44±0.68 to 1.08±0.65 mm Hg; week 6: 0.36±0.63 to 0.68±0.68 mm Hg) at any timepoint (all P > 0.05). AEs were 3-fold greater in the BID arm (41.7%; QD: 14.0%); the most frequently reported AE was conjunctival/ocular hyperemia (BID: 22.9%; QD: 2.0%). Five subjects discontinued omidenepag isopropyl prematurely, 4 of 5 owing to AEs (BID: 4; QD: 0). Conclusion: In this study, the benefit-risk profile of omidenepag isopropyl 0.002% QD was more favorable than the benefit-risk profile of BID. This difference was driven by a higher incidence of local tolerability issues in the BID arm." @default.
- W3147697734 created "2021-04-13" @default.
- W3147697734 creator A5006604133 @default.
- W3147697734 creator A5012011016 @default.
- W3147697734 creator A5014393078 @default.
- W3147697734 creator A5051725756 @default.
- W3147697734 creator A5055379155 @default.
- W3147697734 creator A5066314767 @default.
- W3147697734 creator A5067750117 @default.
- W3147697734 creator A5082093498 @default.
- W3147697734 creator A5085226108 @default.
- W3147697734 date "2021-04-02" @default.
- W3147697734 modified "2023-09-27" @default.
- W3147697734 title "A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)" @default.
- W3147697734 cites W1856328802 @default.
- W3147697734 cites W1973990425 @default.
- W3147697734 cites W2017986453 @default.
- W3147697734 cites W2030672528 @default.
- W3147697734 cites W2034742711 @default.
- W3147697734 cites W2072555446 @default.
- W3147697734 cites W2072814044 @default.
- W3147697734 cites W2079467521 @default.
- W3147697734 cites W2114271694 @default.
- W3147697734 cites W2138342502 @default.
- W3147697734 cites W2160247717 @default.
- W3147697734 cites W2160605010 @default.
- W3147697734 cites W23269542 @default.
- W3147697734 cites W2729341911 @default.
- W3147697734 cites W2783861782 @default.
- W3147697734 cites W2794415504 @default.
- W3147697734 cites W2827702279 @default.
- W3147697734 cites W2884952526 @default.
- W3147697734 cites W2918259642 @default.
- W3147697734 cites W2998880617 @default.
- W3147697734 cites W3024912093 @default.
- W3147697734 cites W1998050535 @default.
- W3147697734 doi "https://doi.org/10.1097/ijg.0000000000001836" @default.
- W3147697734 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8171257" @default.
- W3147697734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33813559" @default.
- W3147697734 hasPublicationYear "2021" @default.
- W3147697734 type Work @default.
- W3147697734 sameAs 3147697734 @default.
- W3147697734 citedByCount "7" @default.
- W3147697734 countsByYear W31476977342022 @default.
- W3147697734 countsByYear W31476977342023 @default.
- W3147697734 crossrefType "journal-article" @default.
- W3147697734 hasAuthorship W3147697734A5006604133 @default.
- W3147697734 hasAuthorship W3147697734A5012011016 @default.
- W3147697734 hasAuthorship W3147697734A5014393078 @default.
- W3147697734 hasAuthorship W3147697734A5051725756 @default.
- W3147697734 hasAuthorship W3147697734A5055379155 @default.
- W3147697734 hasAuthorship W3147697734A5066314767 @default.
- W3147697734 hasAuthorship W3147697734A5067750117 @default.
- W3147697734 hasAuthorship W3147697734A5082093498 @default.
- W3147697734 hasAuthorship W3147697734A5085226108 @default.
- W3147697734 hasBestOaLocation W31476977341 @default.
- W3147697734 hasConcept C118487528 @default.
- W3147697734 hasConcept C126322002 @default.
- W3147697734 hasConcept C168563851 @default.
- W3147697734 hasConcept C197934379 @default.
- W3147697734 hasConcept C203092338 @default.
- W3147697734 hasConcept C2776521421 @default.
- W3147697734 hasConcept C2777288759 @default.
- W3147697734 hasConcept C2778527774 @default.
- W3147697734 hasConcept C2781092963 @default.
- W3147697734 hasConcept C2991803831 @default.
- W3147697734 hasConcept C42219234 @default.
- W3147697734 hasConcept C71924100 @default.
- W3147697734 hasConceptScore W3147697734C118487528 @default.
- W3147697734 hasConceptScore W3147697734C126322002 @default.
- W3147697734 hasConceptScore W3147697734C168563851 @default.
- W3147697734 hasConceptScore W3147697734C197934379 @default.
- W3147697734 hasConceptScore W3147697734C203092338 @default.
- W3147697734 hasConceptScore W3147697734C2776521421 @default.
- W3147697734 hasConceptScore W3147697734C2777288759 @default.
- W3147697734 hasConceptScore W3147697734C2778527774 @default.
- W3147697734 hasConceptScore W3147697734C2781092963 @default.
- W3147697734 hasConceptScore W3147697734C2991803831 @default.
- W3147697734 hasConceptScore W3147697734C42219234 @default.
- W3147697734 hasConceptScore W3147697734C71924100 @default.
- W3147697734 hasIssue "6" @default.
- W3147697734 hasLocation W31476977341 @default.
- W3147697734 hasLocation W31476977342 @default.
- W3147697734 hasLocation W31476977343 @default.
- W3147697734 hasLocation W31476977344 @default.
- W3147697734 hasOpenAccess W3147697734 @default.
- W3147697734 hasPrimaryLocation W31476977341 @default.
- W3147697734 hasRelatedWork W1945693830 @default.
- W3147697734 hasRelatedWork W1975088893 @default.
- W3147697734 hasRelatedWork W1990399595 @default.
- W3147697734 hasRelatedWork W2026300329 @default.
- W3147697734 hasRelatedWork W2159316430 @default.
- W3147697734 hasRelatedWork W2377183459 @default.
- W3147697734 hasRelatedWork W2800602224 @default.
- W3147697734 hasRelatedWork W3184686125 @default.
- W3147697734 hasRelatedWork W4225262907 @default.
- W3147697734 hasRelatedWork W4225759404 @default.
- W3147697734 hasVolume "30" @default.